Skip to main content

Proctitis

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
MesalaminePhase 31 trial
Active Trials
NCT01172444Terminated158Est. Dec 2012
Dr. Falk Pharma
Dr. Falk PharmaGermany - Freiburg
1 program
1
Budesonide 2 mg suppositoryPhase 21 trial
Active Trials
NCT01966783Completed320Est. Aug 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozMesalamine
Dr. Falk PharmaBudesonide 2 mg suppository

Clinical Trials (2)

Total enrollment: 478 patients across 2 trials

Clinical Trial With Mesalamine 1g Suppositories

Start: Jun 2010Est. completion: Dec 2012158 patients
Phase 3Terminated
NCT01966783Dr. Falk PharmaBudesonide 2 mg suppository

Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis

Start: Sep 2013Est. completion: Aug 2015320 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.